Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemEF1063-0967Cat.No.:HY-101510CASNo.:613225-56-2分?式:C??H??N?O?S?分?量:484.59作?靶點(diǎn):Phosphatase作?通路:MetabolicEnzyme/Protease儲(chǔ)存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:100mg/mL(206.36mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM2.0636mL10.3180mL20.6360mL5mM0.4127mL2.0636mL4.1272mL10mM0.2064mL1.0318mL2.0636mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；?旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。儲(chǔ)備液的保存?式和期限：-80°C,6months;-20°C,1month。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?，-20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)?內(nèi)使?。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液，再依次添加助溶劑：(為保證實(shí)驗(yàn)結(jié)果的可靠性，澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請(qǐng)依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:2.5mg/mL(5.16mM);Suspendedsolution;Needultrasonic1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEBIOLOGICALACTIVITY?物活性F1063-0967?種雙特異性磷酸酶26(DUSP26)抑制劑，其IC50值為11.62μM。IC50&TargetIC50:11.62μM(DUSP26)[1]體外研究F1063-0967isaDual-specificityphosphatase26(DUSP26)inhibitorwithanIC50of11.62μM.Atconcentrationabove0.1μM,F1063-0967remarkablyinducesIMR32cellapoptosis.F1063-0967inducesapoptosisinIMR-32celllinewithanIC50valueof4.13μM.F1063-0967hasnoeffectonHL7702cellline,andlittleinhibitioneffectonSH-SY5Ycellline[1].PROTOCOLCellAssay[1]TheIMR-32cellsareplatedin96-wellplateswith1×103cellsperwell.Afterthecellsareallowedtosettlefor24h,F1063-0967(0,10,1,and0.1μM)isadded.AnMTTassayisperformed.ForcelllinesHL7702andSH-SY5Y,thecellsareallowedtosettlefor24h,F1063-0967(10μM)isadded,thenMTTassaysarecarriedoutafter72h[1].MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.REFERENCES[1].RenJX,etal.Identificationofnoveldual-specificityphosphatase26inhibitorsbyahybridvirtualscreeningapproachbasedonpharmacophoreandmoleculardocking.BiomedPharmacother.2017May;89:376-385.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseon